Skip to main content
. 2021 Aug 4;28(6):862–869. doi: 10.1093/ibd/izab192

Table 2.

Medication characteristics of flare and control cases being used at time of flare for flare cases and their matched controls.

Flares (n = 74) Controls (n = 74) P value
Taking ≥ 1 IBD medication 81.1% 85.1% 0.510
No. IBD medications mean (SD) 1.30 (1.17) 1.18 (0.82) 0.464
Immunosuppressant (Ex: Methotrexate) 27.0% 21.6% 0.443
5-ASA 23.0% 25.7% 0.702
ustekinumab 5.4% 8.1% 0.512
Anti-TNF agent 27.0% 33.8% 0.372
vedolizumab 0.0% 1.4% 0.316
Other IBD medication 28.4% 18.9% 0.161
Changed medication/dosage ± 4 weeks of flare 39.2% 9.5% 0.000
Introduced oral corticosteroid ± 4 weeks of flare 21.6% 6.8% 0.010